In 1935, the EKO company, led by its founder Bohumír Rakušan, D.Sc., MPharm., expanded into producing extracts from plant and animal tissues for pharmacological use, inspired by traditional Chinese medicine. This research was known as the “RTN Program.” Products like Floristen, Silexil, Retisin, and Lyastin were successfully tested in multiple clinical trials and were later approved for prescription use in the former Czechoslovakia.

At EkoRTN, we continue the legacy of EKO, which belonged to our founder’s family until its nationalization by the communist regime. The research team persisted under the government-owned SPOFA enterprise, EKO division, still led by Bohumír Rakušan. Following additional clinical trials under new management, the products were approved for production.

• Over 18,000 patients participated in clinical trials

• 17 years of mass production for public healthcare

• 11 years of RTN team research and development

• 13 years of clinical validation under government supervision

• 12 specific therapeutic indications

Research and Development

Our research journey began with a private historical archive containing accounting and inventory records, medical notes, dosage information, scientific evaluations, production protocols, and biochemical analyses. Between 2003 and 2018, we confirmed positive effects at the laboratory level through outsourced custom manufacturing, aligning with historical records of natural treatments for various chronic diseases. This led us to revive the original RTN production for limited use.

Drawing inspiration from history, much like Dr. Rakušan, we restarted production of the original RTN preparations in 2021 for our own needs and those of our families, friends, and supporters. We trust in the results of the RTN Program and wish to share them widely. Employing modern approaches such as QA principles, GMP standards, and private trials with early adopters and volunteers, we aim to develop the best dietary supplements. We focus on the specific chemical composition and biochemistry of the obtained metabolites.

We began with Floristen, the most promising preparation from a medical standpoint, supported by health and nutrition claims published by the European Medicines Agency (EMA) for Hypericum perforatum L., known for its antibiotic effects and efficacy against various viruses.

Each RTN product consists of biomolecules natural to the human body, made from bio-certified raw materials, offering unique support to the immune system. Recognizing that nature’s power can sometimes be potent, it’s essential to respect contraindications and recommended dosages for all our natural preparations. When combining RTN preparations with other medications, participation in private trials managed by RTN Therapeutics is required to define optimal prescriptions under medical supervision.

Retisin (RTN33) and Introsin (RTN122/122K) provide distinct effects individually or in combination with complementary agents. For example, RTN33 with Floristen (RTN118), RTN122 with RTN119 and RTN134/140, or RTN75 and Floristen (RTN118) combined with Lyastin (RTN102).

Production

Our extracts undergo rigorous qualitative and quantitative analyses, prepared at varying concentrations to meet the needs of clinics and other manufacturers. Standard dosages include 2 ml ampoules or 1 fl. oz bottles at optimal concentrations.

To maintain maximum control over production, we have established separate facilities that process carefully selected raw materials for the production of Retisin and Lyastin. This allows us to prepare the raw materials needed for these preparations while adhering to strict quality standards. Additionally, because we harvest St. John’s Wort from our organic farmland within a protected landscape area, we have become certified organic farmers. Consequently, several of our products carry BIO certification.

Floristen

Floristen (20 mg/ml) is a former anti-inflammatory agent used in chronic proliferative inflammations, gynecological conditions, venous inflammations, and pancreatitis, with positive effects observed after strokes. We prepare it from Hypericum perforatum L., focusing on a standardized extract containing flavonol glycosides (isoquercetin, acetylated rutin), and flavonoid aglycones (quercetin, kaempferol).

Retisin

Retisin (0.5 mg/ml) is a former palliative agent in cancer treatment and a natural anabolic extracted from bovine blood. It contains fragments of nuclear, membrane, cytoplasmic, and extracellular proteins, along with free amino acids that serve as building blocks for protein synthesis or act as signaling molecules. Rich in nucleotides functioning as energy sources or signaling molecules, Retisin provides a supportive dose of dietary nucleotides, oligopeptides, essential amino acids, and trace elements inherent to the body.

Lyastin

Lyastin (5 mg/ml) was developed to improve the trophic conditions of non-healing tissues, used in Buerger’s disease, obliterative atherosclerosis, and after frostbite. It contains a wide range of lipid substances, sterols, and phospholipid molecules such as sphingomyelins, phosphatidylcholines, phosphoethanolamines, and triacylglycerides.

Silexil

Silexil (10 mg/ml) is currently under development as a new preparation. The original Silexil was used to treat arthrosis in all localizations due to its phospholipid and lipoprotein components.

Despite well-documented information on the efficacy of the preparations and continued interest from both the general public and professionals, the central commission at the time deemed the RTN preparations ineffective. This led to their removal from the pharmacopeia and the cessation of production.

With today’s advancements in scientific methods and modern analytical tools, we now have better means to thoroughly investigate these preparations. Thanks to these modern techniques, we have been able to confirm the original claims made by the RTN team, supported by contemporary scientific research. Our goal is not only to continue therapeutic programs using these preparations but also to achieve a level of standardization that allows their use in line with modern pharmaceutical standards.